Article Versions Notes

Majala S, Vesterinen T, Seppänen H, Mustonen H, Sundström J, Schalin-Jäntti C, Gullichsen R, Schildt J, Kemppainen J, Arola J, et al. Correlation of Somatostatin Receptor 1–5 Expression, [⁶⁸Ga]Ga-DOTANOC, [¹⁸F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. Cancers. 2022; 14(1):162. https://doi.org/10.3390/cancers14010162

Majala, Susanna, Tiina Vesterinen, Hanna Seppänen, Harri Mustonen, Jari Sundström, Camilla Schalin-Jäntti, Risto Gullichsen, Jukka Schildt, Jukka Kemppainen, Johanna Arola, and et al. 2022. "Correlation of Somatostatin Receptor 1–5 Expression, [⁶⁸Ga]Ga-DOTANOC, [¹⁸F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms" Cancers 14, no. 1: 162. https://doi.org/10.3390/cancers14010162

Majala, S., Vesterinen, T., Seppänen, H., Mustonen, H., Sundström, J., Schalin-Jäntti, C., Gullichsen, R., Schildt, J., Kemppainen, J., Arola, J., & Kauhanen, S. (2022). Correlation of Somatostatin Receptor 1–5 Expression, [⁶⁸Ga]Ga-DOTANOC, [¹⁸F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. Cancers, 14(1), 162. https://doi.org/10.3390/cancers14010162